-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Reiterates Buy on Neumora Therapeutics, Maintains $14 Price Target

Benzinga·03/31/2026 13:15:51
Listen to the news
Guggenheim analyst Yatin Suneja reiterates Neumora Therapeutics (NASDAQ:NMRA) with a Buy and maintains $14 price target.